Search
Recent interest in the diverse ecosystem of bacteria, fungi, parasites, and viruses that make up the skin microbiome has led to several studies investigating the microbiome in healthy skin and in a variety of dermatological conditions.
Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Remote Aboriginal communities in Australia are located on traditional lands holding deep cultural significance and meaning for residents. However, systemic inequity rooted in colonisation has driven persistent housing and health disparities, with inadequate environmental health conditions within homes and communities a prominent example.
The prevalence of impetigo and pharyngitis - which are both superficial group A streptococcus (GAS) infections that precede acute rheumatic fever - is poorly defined. Guidelines recommend the early diagnosis of both infections to prevent ARF; however, screening to enable the concurrent detection of these infections in high-risk populations has rarely been performed.
Although essential for overall health and wellbeing, little is known about skin health in urban-living Australian Aboriginal children. This co-designed, research-service project aimed to describe skin health and document skin disease frequency in urban-living Aboriginal children and young people in Western Australia and investigate housing associations for skin infections.
The urgency for a world-first respiratory syncytial virus vaccine is at an all-time high.
A rapid test to detect antibiotic-resistant skin infections in Aboriginal children could be a step closer, thanks to support from the FHRIF.
The Kids Research Institute Australia, Perth Children’s Hospital (PCH) and the Peter Doherty Institute for Infection and Immunity (Doherty Institute) will spearhead the paediatric arm of a world-first global platform trial designed to uncover treatments for Staphylococcus aureus bloodstream infection.
At least 2,000 WA healthcare workers will help test whether an existing tuberculosis vaccine can reduce their chance of COVID-19 infection, lessen the severity of symptoms and boost immunity.
The Kids Research Institute Australia is now part of an ambitious, yet achievable, global bid to produce such one-shot vaccines.